ClinicalTrials.gg
RecruitingNCT03582189Updated Mar 5, 2026

MR Guidance for Liver and Pancreas

An observational study in Magnetic Resonance Imaging, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by University Health Network, Toronto · Observational

How we know

From the registry’s dates

  • Started Jul 2018; still recruiting 8 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 70 studies in Liver Neoplasms with a site in Canada — 13 open to participants now, 22 under way, 3 of them phase 3. Liver Neoplasms · Canada.

Planned enrollment
12th of 13
30 · median 328
Started
2018
with 7 others
Observational
13 of 70
7 open now
Primary completion
2027-02
later than 10 of 21 live
Registered
45th of 70
by date
Lead sponsor
7 of 70
University Health Network, Toronto

Among the 70 studies in Liver Neoplasms with a site in Canada, this one is the 12th largest by planned enrollment of the 13 observational ones that give a count, is one of 8 that started in 2018, is one of 13 observational ones, reaches primary completion later than 10 of the 21 other live ones, and was the 45th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

13 of the 70 studies in Liver Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Liver Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

This is a single centre, single arm, prospective feasibility study that aims to see whether magnetic resonance imaging (MRI) as a source of image guidance before each radiation treatment fraction is feasible, and also if it may provide information that could potentially be used during the treatment to improve the radiation treatment plan.

Patients will have 5 MRIs with each of their RT sessions. If patients' RT treatment will consist of more than 5 fractions, only 5 MRIs will be done with any 5 RT fractions. Patients will be completing a short questionnaire at the end of each MRI. A patient questionnaire will also be completed at the end of the study to assess for patient satisfaction.

There will be 30 evaluable patients enrolled to the study.

03

Conditions studied

  • Magnetic Resonance Imaging

Keywords

  • Liver Cancer
  • Pancreatic Cancer
  • Radiation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with locally advanced pancreatic cancer or hepatocellular carcinoma being considered for treatment with chemoradiation, long course RT, or SBRT with curative intent or palliative intent, planned for 5 or more RT fractions

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years or older
  • Diagnosed with locally advanced pancreatic cancer or hepatocellular carcinoma being considered for treatment with chemoradiation, long course RT, or SBRT with curative intent or palliative intent, planned for 5 or more RT fractions

Exclusion criteria

Exclusion Criteria:

- for MRI: ferromagnetic prosthesis, pacemaker / implanted defibrillator, claustrophobia

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pancreatic Cancer

    Approximately 10 patients with pancreatic cancer will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment

    Other: MRI

  • Liver Metastases

    Approximately 10 patients with liver mets will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment

    Other: MRI

  • Hepatocellular carcinoma

    Approximately 10 patients with HCC will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment

    Other: MRI

Interventions

  • OtherMRI

    Patients who consent to this study will have an abdominal MRI prior to or immediately after each fraction of radiation treatment in the case of those patients that are undergoing SBRT or those receiving palliative treatment. On patients receiving definitive chemoradiation, an abdominal MRI will be performed prior to or immediately after radiation treatment once per week during the any five weeks of treatment

06

What researchers measure

Primary outcomes

  1. Patient Satisfaction Survey

    To evaluate patient satisfaction with the MR guidance process, a modified version of a questionnaire previously used at our institution will be performed at the end of the study

    Time frame: At study completion (day5 or week 5, depending on type of treatment)

  2. MRI-Anxiety Questionnaire

    This instrument will be used to evaluate patient related anxiety after each MR

    Time frame: Prior to or before MR session 1 (day 1 or week 1, depending on type of treatment)

  3. MRI-Anxiety Questionnaire

    This instrument will be used to evaluate patient related anxiety after each MR

    Time frame: Prior to or before MR session 2 (day 2 or week 2, depending on type of treatment)

  4. MRI-Anxiety Questionnaire

    This instrument will be used to evaluate patient related anxiety after each MR

    Time frame: Prior to or before MR session 3 (day 3 or week 3, depending on type of treatment)

  5. MRI-Anxiety Questionnaire

    This instrument will be used to evaluate patient related anxiety after each MR

    Time frame: Prior to or before MR session 4 (day 4 or week 4, depending on type of treatment)

  6. MRI-Anxiety Questionnaire

    his instrument will be used to evaluate patient related anxiety after each MR

    Time frame: Prior to or before MR session 5 (day 5 or week 5, depending on type of treatment)

07

Study locations

1 of 1 sites recruiting
  • University Health Network - Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Laura Dawson, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2018 (actual). Primary completion is estimated for Feb 2027, 103 months after the start.

Of 132 non-industry observational studies under Liver Neoplasms, half reached primary completion within 114 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 172. This study's planned 103 months is close to that.

Counting every sponsor, half of 160 studies reached it within 59 months; a quarter within 34 and three quarters within 172.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2018
First posted
Jul 10, 2018
StartActual
Jul 11, 2018
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03582189
Responsible party
Sponsor
First posted
Jul 10, 2018
Start date
Jul 11, 2018
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

Edel Sexton
Contact
Edel.Sexton@uhn.ca
416-946-4501 ext. 5576
Jana Huang
Contact
Jana.Huang@uhnresearch.ca
Laura Dawson, MD
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion